In this SOHO Insider roundtable discussion, Charalambos (Babis) Andreadis, MD, MS, professor of clinical medicine at University of California, San Francisco, moderates a discussion on CELLMods in lymphoma.
The panelists include Jason Westin, MD, associate professor in the Department of Lymphoma/Myeloma at University of Texas MD Anderson Cancer Center; Loretta Nastoupil, MD, section chief of indolent lymphoma and director of clinical research at Common Spirit Health; and Swetha Thiruvengadam, MD, assistant clinical professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
In this video, the panel discusses promising future combinations in follicular lymphoma, highlighting novel agents paired with rituximab, bispecific antibodies, and CELMoDs like golcadomide in frontline and relapsed settings, while stressing the need for longer follow-up and optimal sequencing.
“This is a great time for both large B-cell and follicular lymphoma patients. We have really good treatment strategies,” Dr. Thiruvengadam said.
Watch more videos from this discussion.
This video is being brought to you by an education grant by Bristol Myers Squibb.
